Current research into treatments for BRCA-related breast cancer and the phase 3 EMBRACA trial
Dr Kelly focuses on the phase 3 EMBRACA study, which is evaluating the PARP inhibitor, talazoparib, versus physician’s choice in patients with locally advanced and/or metastatic BRCA-related breast cancer.